Tags

Type your tag names separated by a space and hit enter

Alternate delivery systems for contraceptive progestogens.
Fertil Steril. 1988 May; 49(5 Suppl 2):16S-30S.FS

Abstract

Research continues toward developing an universally acceptable, safe, and effective contraceptive to inhibit the female reproductive process. Progestational systems, either alone or in combination with small amounts of estrogen, approach such an ideal. The pregnane and 19-nortestosterone progestins were examined in this review with regard to contraceptive mechanisms of action and major side effects, such as menstrual abnormalities, metabolic changes, neoplasia, and teratogenicity. These steroids provide highly effective and long-acting contraception, and bypass the oral route of administration, resulting in fewer gastrointestinal and systemic side effects. Data regarding the lack of a deleterious effect of contraceptive progestogens on fetal malformation or cancer of the breast and genital tract reinforce their safety. Further study and refinement are needed, however, to lower the incidence of menstrual abnormalities, hypertension, and detrimental lipid alterations prior to approval for general use.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Wayne State University School of Medicine, C. S. Mott Center for Human Growth and Development, Detroit, Michigan.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

3282932

Citation

Ginsburg, K A., and K S. Moghissi. "Alternate Delivery Systems for Contraceptive Progestogens." Fertility and Sterility, vol. 49, no. 5 Suppl 2, 1988, 16S-30S.
Ginsburg KA, Moghissi KS. Alternate delivery systems for contraceptive progestogens. Fertil Steril. 1988;49(5 Suppl 2):16S-30S.
Ginsburg, K. A., & Moghissi, K. S. (1988). Alternate delivery systems for contraceptive progestogens. Fertility and Sterility, 49(5 Suppl 2), 16S-30S.
Ginsburg KA, Moghissi KS. Alternate Delivery Systems for Contraceptive Progestogens. Fertil Steril. 1988;49(5 Suppl 2):16S-30S. PubMed PMID: 3282932.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alternate delivery systems for contraceptive progestogens. AU - Ginsburg,K A, AU - Moghissi,K S, PY - 1988/5/1/pubmed PY - 1988/5/1/medline PY - 1988/5/1/entrez KW - Biology KW - Cardiovascular Effects KW - Contraception KW - Contraceptive Agents, Female KW - Contraceptive Agents, Progestin--beneficial effects KW - Contraceptive Agents, Progestin--pharmacodynamics KW - Contraceptive Agents, Progestin--side effects KW - Contraceptive Agents--beneficial effects KW - Contraceptive Agents--pharmacodynamics KW - Contraceptive Agents--side effects KW - Corpus Luteum Hormones KW - Diseases KW - Economic Factors KW - Endocrine System KW - Estrogens--side effects KW - Family Planning KW - Genital Effects, Female KW - Genitalia KW - Genitalia, Female KW - Hormones KW - Lipid Metabolic Effects KW - Lipids KW - Literature Review KW - Menstruation Disorders KW - Metabolic Effects KW - Physiology KW - Progestational Hormones KW - Progesterone--side effects KW - Reproductive Control Agents KW - Research And Development KW - Technology KW - Urogenital Effects KW - Urogenital System SP - 16S EP - 30S JF - Fertility and sterility JO - Fertil Steril VL - 49 IS - 5 Suppl 2 N2 - Research continues toward developing an universally acceptable, safe, and effective contraceptive to inhibit the female reproductive process. Progestational systems, either alone or in combination with small amounts of estrogen, approach such an ideal. The pregnane and 19-nortestosterone progestins were examined in this review with regard to contraceptive mechanisms of action and major side effects, such as menstrual abnormalities, metabolic changes, neoplasia, and teratogenicity. These steroids provide highly effective and long-acting contraception, and bypass the oral route of administration, resulting in fewer gastrointestinal and systemic side effects. Data regarding the lack of a deleterious effect of contraceptive progestogens on fetal malformation or cancer of the breast and genital tract reinforce their safety. Further study and refinement are needed, however, to lower the incidence of menstrual abnormalities, hypertension, and detrimental lipid alterations prior to approval for general use. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/3282932/Alternate_delivery_systems_for_contraceptive_progestogens_ DB - PRIME DP - Unbound Medicine ER -